Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wuhan Univ. ERα compound 17e: sourced facts only. name: "In this regard, we developed and studied a novel ERα degrader, which is a PROTAC-like SERD named 17e." [PMID:36905762]; target: "In this regard, we developed and studied a novel ERα degrader, which is a PROTAC-like SERD named 17e." [PMID:36905762]; developer: "Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Bayi Road, Wuhan, Hubei 430072, China." [PMID:36905762]; modality: "In this regard, we developed and studied a novel ERα degrader, which is a PROTAC-like SERD named 17e." [PMID:36905762]; stage: "We found that compound 17e can inhibit the growth of BC both in vitro and in vivo and induce the cell cycle arrest of BC." [PMID:36905762]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wuhan Univ. ERα compound 17e.